{
    "@graph": [
        {
            "@id": "https://www.tib.eu/de/suchen/id/TIBKAT%3A169562727X",
            "@type": "bibo:Book",
            "P1053": "1 Online-Ressource (xxi, 359 Seiten)",
            "contributor": [
                "Crews, Craig",
                "Weinmann, Hilmar"
            ],
            "description": [
                "Illustrationen",
                "Campusweiter Zugriff (Universit\u00e4t Hannover) - Vervielf\u00e4ltigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots"
            ],
            "identifier": [
                "(isbn13)9781839160776",
                "(doi)10.1039/9781839160691",
                "(firstid)KXP:169562727X",
                "(ppn)169562727X",
                "(isbn13)9781839160691"
            ],
            "publisher": "Royal Society of Chemistry",
            "subject": [
                "Drugs",
                "(classificationName=loc)RS420",
                "Proteolysis",
                "Electronic books",
                "(classificationName=linseach:mapping)rest",
                "(classificationName=ddc)615.19",
                "Drugs ; Design"
            ],
            "title": "Protein degradation with new chemical modalities : successful strategies in drug discovery and chemical biology",
            "abstract": [
                "Cover -- Half Title -- Series Information -- Title Page -- Copyright Page -- Preface -- Contents -- Chapter 1 PROTAC-mediated Target Degradation: A Paradigm Changer in Drug Discovery? -- References -- Chapter 2 Structural and Biophysical Principles of Degrader Ternary Complexes -- 2.1 Introduction -- 2.1.1 Mechanistic Advantages of Targeted Protein Degradation -- 2.1.1.1 Immediate Advantages of Degradation Versus Inhibition -- 2.1.1.2 Differentiation of Degraders due to Their Mode of Action -- 2.1.2 History of PROTACs (2001-2010) -- 2.1.3 Small-molecule VHL- and CRBN-based PROTACs (2010-2015)",
                "2.3.5.2 Bioluminescence Resonance Energy Transfer (BRET) -- 2.4 Concluding Remarks -- 2.5 Acknowledgments -- 2.5.1 Funding -- 2.5.2 Conflict of Interest Statement -- References -- Chapter 3 Immediate and Selective Control of Protein Abundance Using the dTAG System -- 3.1 The Potential and Limitations of Targeted Protein Degradation -- 3.2 Chemical-Genetic Degradation Approaches -- 3.3 Development of the dTAG Platform -- 3.4 Genetic Methods to Express FKBP12F36V-fusions -- 3.4.1 Ectopic Expression of FKBP12F36V-fusions -- 3.4.2 Knock-in Strategies to Express FKBP12F36V-fusions",
                "3.5 Strategies Towards Identification of a Lead dTAG Molecule -- 3.5.1 Biochemical Assays for FKBP12F36V and E3 Ligase Binding -- 3.5.2 Determining FKBP12F36V-specific Degradation in Cells -- 3.5.3 Requirement of E3 Ligase and Proteasome -- 3.5.4 Assessment of dTAG Molecule Selectivity -- 3.5.5 In Vivo Assessment of dTAG Molecule Activity -- 3.6 Case Studies Employing the dTAG Platform -- 3.6.1 Target Validation Using dTAG -- 3.6.2 Targeting Recalcitrant Oncoproteins Using dTAG -- 3.6.3 Targeting Essential Transcriptional Regulators Using dTAG",
                "2.3.1 Can My PROTAC Form a Ternary Complex? -- 2.3.1.1 Pull-down Assays -- 2.3.1.2 Proximity-based Ternary Assays: AlphaScreen/LISA and TR-FRET -- 2.3.1.3 Surface Plasmon Resonance -- 2.3.2 How Tightly Does My Ternary Complex Bind? -- 2.3.2.1 Competition Assays -- 2.3.2.2 Direct Binding Assays -- 2.3.3 To What Extent Is My Ternary Complex Cooperative? -- 2.3.4 How Long Does My Ternary Complex Last? -- 2.3.5 Does the PROTAC Induce Ternary Complex Formation in Cells? -- 2.3.5.1 Separation of Phases-based Protein Interaction Reporter Assay (SPPIER)",
                "This book provides a comprehensive overview from the leading academic and industrial experts on recent developments, scope and limitations in this dynamically growing research area; an ideal reference work for researchers in drug discovery and chemical biology as well as advanced students",
                "2.2 Structural Features of Ternary Complexes -- 2.2.1 Ternary Complex Equilibria and Definitions -- 2.2.2 Structural Elucidation of PROTAC Ternary Complexes -- 2.2.2.1 The First PROTAC Ternary Complex Crystal Structure: VHL:MZ1:Brd4BD2 -- 2.2.2.2 Structure-guided design of SMARCA2/4 PROTACs -- 2.2.2.3 Ternary Structures of CRBN-based PROTACs -- 2.2.3 Degraders as Monovalent Molecular Glues -- 2.2.3.1 Cereblon-targeting Immunomodulatory Drugs -- 2.2.3.2 DCAF15-targeting Sulfonamide Drugs -- 2.2.4 Surface Areas Buried by PROTACs and Monovalent Glues -- 2.3 Ternary Assays"
            ],
            "dcterms:contributor": "Technische Informationsbibliothek (TIB)",
            "isPartOf": "(collectioncode)ZDB-1-RSEK",
            "issued": "2021",
            "language": "http://id.loc.gov/vocabulary/iso639-1/en",
            "license": "commercial licence",
            "medium": "rda:termList/RDACarrierType/1018",
            "volume": "74",
            "isLike": "doi:10.1039/9781839160691",
            "P30128": "RSC drug discovery",
            "P60163": "Cambridge"
        }
    ],
    "@id": "urn:x-arq:DefaultGraphNode",
    "@context": {
        "publisher": "http://purl.org/dc/elements/1.1/publisher",
        "volume": "http://purl.org/ontology/bibo/volume",
        "issued": "http://purl.org/dc/terms/issued",
        "subject": "http://purl.org/dc/elements/1.1/subject",
        "title": "http://purl.org/dc/elements/1.1/title",
        "identifier": "http://purl.org/dc/elements/1.1/identifier",
        "medium": {
            "@id": "http://purl.org/dc/terms/medium",
            "@type": "@id"
        },
        "abstract": "http://purl.org/dc/terms/abstract",
        "license": "http://purl.org/dc/terms/license",
        "contributor": "http://purl.org/dc/elements/1.1/contributor",
        "description": "http://purl.org/dc/elements/1.1/description",
        "P60163": "http://www.rdaregistry.info/Elements/u/#P60163",
        "language": {
            "@id": "http://purl.org/dc/terms/language",
            "@type": "@id"
        },
        "isPartOf": "http://purl.org/dc/terms/isPartOf",
        "P30128": "http://www.rdaregistry.info/Elements/m/#P30128",
        "P1053": "http://iflastandards.info/ns/isbd/elements/P1053",
        "isLike": {
            "@id": "http://umbel.org/umbel#isLike",
            "@type": "@id"
        },
        "umbel": "http://umbel.org/umbel#",
        "rdau": "http://www.rdaregistry.info/Elements/u/#",
        "owl": "http://www.w3.org/2002/07/owl#",
        "dcterms": "http://purl.org/dc/terms/",
        "bibo": "http://purl.org/ontology/bibo/",
        "rdam": "http://www.rdaregistry.info/Elements/m/#",
        "gnd": "http://d-nb.info/gnd/",
        "isbd": "http://iflastandards.info/ns/isbd/elements/",
        "rda": "http://rdvocab.info/",
        "doi": "https://doi.org/"
    }
}